20:49 , May 24, 2019 |  BioCentury  |  Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

It is clear that Europe has hotspots of innovation that are discovering and developing the next wave of new therapeutic modalities. Nearly every category of new modality has a European champion, with clusters forming around...
16:29 , Apr 2, 2019 |  BC Extra  |  Financial News

Ocular oncology play Aura raises $40M D round

Medicxi led a $40 million series D round for Aura as the ocular oncology company prepares its lead choroidal melanoma therapy for Phase III testing in 1H20. The funding will give Aura Biosciences Inc. (Cambridge,...
22:40 , Mar 18, 2019 |  BC Extra  |  Financial News

OrbiMed, Arix lead Imara's $63M B round

Imara will use its $63 million series B round to prepare lead compound IMR-687 for a Phase III program in adults with sickle cell disease, and to position the oral phosphodiesterase-9 (PDE-9) inhibitor for pediatric...
00:10 , Feb 20, 2019 |  BC Extra  |  Company News

Management tracks: Allergan, Arix, Quest, SurModics

Allergan plc (NYSE:AGN) appointed Robert Hugin to its board. He stepped down as CEO of Celgene Corp. (NASDAQ: CELG) in 2016, and retired as Celgene's executive chairman last year. Mark Alles is Celgene's current chairman...
23:30 , Feb 13, 2019 |  BC Week In Review  |  Financial News

Harpoon slips after pricing $75.6M IPO

Harpoon Therapeutics Inc. (NASDAQ:HARP) raised $75.6 million in an IPO that priced at the midpoint of its proposed range. Harpoon sold 5.4 million shares at $14, within the $13-$15 range. The price gave Harpoon a...
04:00 , Feb 8, 2019 |  BC Extra  |  Financial News

Harpoon slips after pricing $75.6M IPO

Harpoon Therapeutics Inc. (NASDAQ:HARP) shares lost $0.50 to $13.50 in their first day of trading Friday after the company raised $75.6 million in an IPO that priced at the midpoint of its proposed range. Harpoon...
21:35 , Jan 11, 2019 |  BioCentury  |  Emerging Company Profile

Artios: Probing DNA Damage

With programs in-licensed from Cancer Research UK and Masaryk University, Artios Pharma Ltd. thinks it has next-generation DNA damage response programs that could improve upon PARP inhibitors -- and the funds to take them to...
22:03 , Jan 4, 2019 |  BC Week In Review  |  Financial News

On heels of series C, Harpoon files for IPO

Less than two months after raising a $70 million series C round, Harpoon Therapeutics Inc. (South San Francisco, Calif.) filed on Dec. 27 to raise $86.3 million in an IPO on NASDAQ. Harpoon is developing...
23:06 , Dec 27, 2018 |  BC Extra  |  Financial News

On heels of series C, Harpoon files for IPO

Less than two months after raising a $70 million series C round, Harpoon Therapeutics Inc. (South San Francisco, Calif.) filed Thursday to raise $86.3 million in an IPO on NASDAQ. Harpoon is developing tri-specific T...
15:57 , Nov 16, 2018 |  BC Week In Review  |  Financial News

Harpoon raises $70M ahead of additional Phase I starts for TriTACs

Harpoon Therapeutics Inc. (South San Francisco, Calif.) raised $70 million on Nov. 11 in a series C round led by new investor OrbiMed Advisors, as the immunotherapy company gears up to bring two more of...